Sayed Osama, MD
Nephrology · Flint, MINPI 1467442038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $925, 4.0 times the $231 reported in 2019.
Across 156 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$364
- AstraZeneca$298
- Otsuka America Pharmaceutical, Inc.$232
- Vifor Pharma, Inc.$227
- Akebia Therapeutics Inc$225
- Travere Therapeutics, Inc.$194
- plus $2K from 18 others
Across 1 payment — averaging $8035.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$8K
What the payments were for
- Food & beverage$2,91294%
- Education$1786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $364 |
| AstraZeneca(2 entities) | 16 | $298 |
| Otsuka America Pharmaceutical, Inc. | 7 | $232 |
| Vifor Pharma, Inc. | 14 | $227 |
| Akebia Therapeutics Inc | 12 | $225 |
| Travere Therapeutics, Inc. | 10 | $194 |
| Calliditas Therapeutics US Inc. | 11 | $194 |
| Boehringer Ingelheim | 9 | $169 |
| Bayer | 8 | $167 |
| OPKO Pharmaceuticals, LLC | 8 | $149 |
| Fresenius USA Marketing, Inc. | 5 | $133 |
| Recor Medical Inc | 4 | $121 |
| Scpharmaceuticals Inc. | 6 | $119 |
| Sanofi | 6 | $101 |
| Aurinia Pharma U.S., Inc. | 4 | $90 |
| Novartis | 3 | $56 |
| Cormedix Inc. | 2 | $46 |
| GSK | 3 | $43 |
| Novo Nordisk | 2 | $42 |
| Lilly USA, LLC | 2 | $34 |
| Chiesi USA, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$3,089 in reported general payments places this provider in the 75th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 77 | $291,676 |
| JardianceEmpagliflozin | 224 | $253,093 |
| MounjaroTirzepatide | 127 | $186,702 |
| OzempicSemaglutide | 138 | $185,827 |
| TrulicityDulaglutide | 83 | $122,577 |
| FarxigaDapagliflozin Propanediol | 82 | $72,421 |
| LokelmaSodium Zirconium Cyclosilicate | 69 | $48,357 |
| AuryxiaFerric Citrate | 13 | $37,113 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $31,724 |
| Sevelamer Carbonate | 102 | $17,864 |
| EntrestoSacubitril/Valsartan | 16 | $14,931 |
| ClinisolParenteral Amino Acid 15% No.5 | 75 | $14,753 |
| Bydureon BciseExenatide Microspheres | 11 | $10,617 |
| Calcium Acetate | 93 | $8,343 |
| Cinacalcet Hcl | 33 | $6,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $34 | $309,279210 claims |
| Boehringer IngelheimJardiance | $169 | $253,093224 claims |
| Novo NordiskOzempic | $42 | $185,827138 claims |
| AstraZenecaFarxiga, Lokelma | $298 | $120,778151 claims |
| Akebia Therapeutics IncAuryxia | $225 | $37,11313 claims |
| NovartisEntresto | $56 | $14,93116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 325 nephrology providers in Michigan.
Other nephrology in Flint
- Senthil RamaiyahFlint$19K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.